Summary by Futu AI
On May 31, 2024, Huabo Medicine-B (Hepo Medicine-B) submitted a monthly report on stock changes, which showed that the company's statutory/registered capital stock remained unchanged in May 2024, with a total of $500,000. The number of issued shares increased from 768,490,410 to 768,876,410, an increase of 386,000 common shares. These new shares came from the exercise of the share purchase plan after the initial public offering, and brought in HKD 525,732 in funds for the company. The report was resubmitted to Hong Kong Exchanges and Clearing Limited by Executive Director Wang Jinsong on June 12, 2024, confirming that all transactions comply with relevant listing rules and legal regulations.